UBS Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28.3M | Buy |
1,007,331
+490,700
| +95% | +$13.1M | ﹤0.01% | 2220 |
|
|
2025
Q4 | $12.9M | Buy |
516,631
+4,518
| +0.9% | +$114K | ﹤0.01% | 3032 |
|
|
2025
Q3 | $13M | Sell |
512,113
-55,500
| -10% | -$1.37M | ﹤0.01% | 3015 |
|
|
2025
Q2 | $13.8M | Sell |
567,613
-1,325,100
| -70% | -$30.9M | ﹤0.01% | 2777 |
|
|
2025
Q1 | $48M | Buy |
1,892,713
+172,300
| +10% | +$4.51M | 0.01% | 1513 |
|
|
2024
Q4 | $45.6M | Sell |
1,720,413
-189,300
| -10% | -$5.13M | 0.01% | 1543 |
|
|
2024
Q3 | $55.3M | Buy |
1,909,713
+719,400
| +60% | +$21M | 0.01% | 1085 |
|
|
2024
Q2 | $33.3M | Buy |
1,190,313
+167,513
| +16% | +$4.61M | 0.01% | 1311 |
|
|
2024
Q1 | $28.4M | Sell |
1,022,800
-1,963,223
| -66% | -$54.5M | 0.01% | 1423 |
|
|
2023
Q4 | $86M | Buy |
2,986,023
+1,680,923
| +129% | +$50.8M | 0.03% | 655 |
|
|
2023
Q3 | $43.3M | Sell |
1,305,100
-126,000
| -9% | -$4.46M | 0.01% | 948 |
|
|
2023
Q2 | $52.5M | Buy |
1,431,100
+414,400
| +41% | +$16.1M | 0.02% | 805 |
|
|
2023
Q1 | $41.5M | Sell |
1,016,700
-724,900
| -42% | -$31.3M | 0.02% | 885 |
|
|
2022
Q4 | $89.2M | Buy |
1,741,600
+378,100
| +28% | +$18.1M | 0.03% | 535 |
|
|
2022
Q3 | $59.7M | Sell |
1,363,500
-670,000
| -33% | -$32.6M | 0.03% | 611 |
|
|
2022
Q2 | $107M | Sell |
2,033,500
-164,800
| -7% | -$8.4M | 0.04% | 427 |
|
|
2022
Q1 | $114M | Sell |
2,198,300
-3,558,334
| -62% | -$185M | 0.04% | 477 |
|
|
2021
Q4 | $340M | Buy |
5,756,634
+2,841,355
| +97% | +$141M | 0.1% | 211 |
|
|
2021
Q3 | $125M | Sell |
2,915,279
-586,709
| -17% | -$26M | 0.04% | 457 |
|
|
2021
Q2 | $137M | Buy |
3,501,988
+20,328
| +0.6% | +$791K | 0.04% | 412 |
|
|
2021
Q1 | $126M | Buy |
3,481,660
+2,892,407
| +491% | +$103M | 0.04% | 418 |
|
|
2020
Q4 | $21.7M | Sell |
589,253
-1,108,214
| -65% | -$40.6M | 0.01% | 1293 |
|
|
2020
Q3 | $59.1M | Sell |
1,697,467
-20,975
| -1% | -$735K | 0.02% | 580 |
|
|
2020
Q2 | $53.3M | Sell |
1,718,442
-313,775
| -15% | -$10.7M | 0.02% | 573 |
|
|
2020
Q1 | $62.9M | Buy |
2,032,217
+994,870
| +96% | +$33.9M | 0.03% | 462 |
|
|
2019
Q4 | $38.6M | Sell |
1,037,347
-207,111
| -17% | -$7.38M | 0.01% | 921 |
|
|
2019
Q3 | $42.4M | Buy |
1,244,458
+597,934
| +92% | +$21.7M | 0.02% | 777 |
|
|
2019
Q2 | $26.6M | Buy |
646,524
+160,946
| +33% | +$6.39M | 0.01% | 1028 |
|
|
2019
Q1 | $19.6M | Sell |
485,578
-885,571
| -65% | -$35.5M | 0.01% | 1160 |
|
|
2018
Q4 | $56.8M | Buy |
1,371,149
+447,634
| +48% | +$18.6M | 0.03% | 544 |
|
|
2018
Q3 | $38.6M | Buy |
923,515
+187,823
| +26% | +$7.23M | 0.02% | 808 |
|
|
2018
Q2 | $25.3M | Buy |
735,692
+7,905
| +1% | +$270K | 0.01% | 1020 |
|
|
2018
Q1 | $24.5M | Sell |
727,787
-45,217
| -6% | -$1.55M | 0.01% | 1012 |
|
|
2017
Q4 | $26.6M | Sell |
773,004
-291,220
| -27% | -$9.93M | 0.01% | 1009 |
|
|
2017
Q3 | $36M | Buy |
1,064,224
+653,480
| +159% | +$21M | 0.02% | 773 |
|
|
2017
Q2 | $13.1M | Sell |
410,744
-218,178
| -35% | -$6.88M | 0.01% | 1318 |
|
|
2017
Q1 | $20.4M | Sell |
628,922
-234,726
| -27% | -$7.4M | 0.01% | 1018 |
|
|
2016
Q4 | $26.6M | Buy |
863,648
+341,602
| +65% | +$10.4M | 0.01% | 855 |
|
|
2016
Q3 | $16.8M | Sell |
522,046
-308,295
| -37% | -$10.3M | 0.01% | 1081 |
|
|
2016
Q2 | $27.7M | Sell |
830,341
-780,803
| -48% | -$24.9M | 0.02% | 750 |
|
|
2016
Q1 | $45.3M | Sell |
1,611,144
-1,941,363
| -55% | -$55.5M | 0.03% | 504 |
|
|
2015
Q4 | $109M | Buy |
3,552,507
+2,430,840
| +217% | +$76.5M | 0.07% | 275 |
|
|
2015
Q3 | $33.4M | Sell |
1,121,667
-317,675
| -22% | -$10.2M | 0.02% | 630 |
|
|
2015
Q2 | $45.8M | Sell |
1,439,342
-693,638
| -33% | -$22.6M | 0.03% | 557 |
|
|
2015
Q1 | $70.4M | Sell |
2,132,980
-3,354,776
| -61% | -$107M | 0.05% | 405 |
|
|
2014
Q4 | $162M | Buy |
+5,487,756
| New | +$157M | 0.11% | 197 |
|
Other funds holding PFE
VCM
VPM
UBS Group's PFE Position: Q1 2026 in Review
UBS Group increased its Pfizer (PFE) stake by 4.8% in Q1 2026, buying an estimated $21.6M and bringing the position to 17,609,150 shares worth $494M. The position accounts for 0.07% of the portfolio, ranked #272.
UBS Group first reported a position in PFE in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.03B in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- UBS Group held 17,609,150 shares of Pfizer worth $494M as of Q1 2026.
- UBS Group bought 811,135 Pfizer shares in Q1 2026, an estimated $21.6M.
- Pfizer made up 0.07% of UBS Group's portfolio in Q1 2026, its #272 holding.
- UBS Group first reported a position in Pfizer in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Pfizer position peaked at $1.03B in Q4 2021.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.